Mizuho Markets Americas LLC Sells 15,116 Shares of Haemonetics Co. (NYSE:HAE)

Mizuho Markets Americas LLC trimmed its stake in Haemonetics Co. (NYSE:HAE) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 348,478 shares of the medical instruments supplier’s stock after selling 15,116 shares during the period. Mizuho Markets Americas LLC owned about 0.68% of Haemonetics worth $28,011,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Quarry LP bought a new position in Haemonetics during the 2nd quarter worth approximately $39,000. Covestor Ltd raised its stake in Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in Haemonetics during the 2nd quarter worth about $82,000. Canada Pension Plan Investment Board acquired a new stake in Haemonetics during the 2nd quarter worth about $83,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Haemonetics in the 1st quarter valued at about $86,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HAE. Raymond James upgraded Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a report on Friday, November 8th. CL King initiated coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price for the company. Citigroup cut their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a report on Friday, November 8th. Finally, BTIG Research began coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Stock Down 1.7 %

Haemonetics stock opened at $89.24 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. The company has a market capitalization of $4.48 billion, a P/E ratio of 37.03, a P/E/G ratio of 1.43 and a beta of 0.32. The firm has a 50 day moving average price of $77.55 and a 200-day moving average price of $82.75. Haemonetics Co. has a twelve month low of $70.25 and a twelve month high of $97.97.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The business had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the business posted $0.99 earnings per share. As a group, equities analysts predict that Haemonetics Co. will post 4.59 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.